RK-582
/ Riken
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
RK-582, a tankyrase inhibitor, attacks Wnt-driven colorectal cancer cells with short-type APC mutations and high β-catenin expression
(AACR 2026)
- "In summary, RK-582 targets the Wnt/β-catenin pathway, a key cancer pathway previously considered undruggable. An investigator-initiated first-in-human clinical trial of this drug is currently ongoing, and these findings are expected to contribute to the development of an innovative therapy for unresectable advanced and recurrent CRC."
First-in-human • IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • APC • AXIN1 • BRAF • CTNNB1 • KRAS • PIK3CA
1 to 1
Of
1
Go to page
1